Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
8.77
-0.02 (-0.23%)
Jun 27, 2025, 4:00 PM - Market closed
Immunome Employees
Immunome had 118 employees as of December 31, 2024. The number of employees increased by 63 or 114.55% compared to the previous year.
Employees
118
Change (1Y)
63
Growth (1Y)
114.55%
Revenue / Employee
$92,695
Profits / Employee
-$1,738,229
Market Cap
763.10M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 118 | 63 | 114.55% |
| Dec 31, 2023 | 55 | 18 | 48.65% |
| Dec 31, 2022 | 37 | -2 | -5.13% |
| Dec 31, 2021 | 39 | 16 | 69.57% |
| Dec 31, 2020 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMNM News
- 22 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Immunome to Present at Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Immunome Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 2 months ago - Immunome: Transformed Pipeline Offers Multiple Catalysts - Seeking Alpha
- 3 months ago - Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference - Business Wire
- 3 months ago - Immunome Reports Full Year 2024 Financial Results and Provides Business Update - Business Wire
- 3 months ago - Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC - Business Wire
- 4 months ago - Immunome to Present at Upcoming March Conferences - Business Wire